Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7681 results

  1. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  3. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  4. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  5. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  6. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  8. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 16 July 2025

    NICE guideline
    In development

  10. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]: evaluation consultation

    We are listening to your views on this Highly specialised technology. Comments close 21 November 2024.

    Highly specialised technologies guidance
    In consultation

  11. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: 31 March 2025

    Health technology evaluations
    In development

  12. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  13. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  15. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

    In development [GID-TA11248] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development